Navigation Links
QIAGEN Acquires ESE GmbH
Date:1/12/2010

t QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

About ESE:

ESE GmbH ESE GmbH is a high-tech enterprise focused on the developing and OEM manufacturing of innovative optical measurement devices for medical, environmental and industrial applications. The company is based in Stockach and employs a staff of 36. More information on

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
2. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
3. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
4. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
5. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
6. WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Inc. (Nasdaq: BNVI ) announced today that it will ... 2009 ended September 30, 2009 on Thursday, November 5, 2009. ... to review the financial results on Thursday, November 5, 2009 ... call by dialing (800) 860-2442 or (412) 858-4600, or can ...
... October 29 Amsterdam Molecular,Therapeutics (AMT) and Progenika Biopharma ... and commercialization agreement for,LPLchip(TM), a diagnostic tool to rapidly ... AMT has developed Glybera(R) as,a gene therapy for patients ... June of this year AMT announced new clinical data ...
Cached Medicine Technology:AMT Starts Development LPLChip(TM) With Progenika 2AMT Starts Development LPLChip(TM) With Progenika 3
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... Steven Reinberg HealthDay ... New guidelines from the American Diabetes Association (ADA) call for ... with diabetes to help prevent heart disease. These new ... of Cardiology and American Heart Association, which also recommend giving ... heart disease, including people with diabetes. "We agree that ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... ATLANTA, Sept. 23 The Hospital of Central Connecticut (THOCC), ... IM Practice Manager to automate, organize and increase quality of ... physicians at THOCC will be using IM,s handheld and Internet-based solution, ... users, making it the most widely used electronic charge capture system ...
... , SALT LAKE CITY, Sept. 23 Dynatronics Corporation ... quarter and year ended June 30, 2009 during the morning of Friday, ... its third consecutive quarter of profitability. , , Dynatronics ... p.m. ET to discuss its results for the quarter and year periods. ...
... , , ROCHESTER, N.Y., Sept. 23 ... R. Kerry Clark and Robert J. Palmisano have joined its board ... outstanding business leaders with broad and relevant experience," said Gerald M. ... these help us become better positioned for long-term growth. We welcome ...
... Foundation recently received a $1 million planned-gift donation ... radiology fellows to pursue this medical profession. SIR ... of interventional radiology by specializing in developing investigators ... research. "This enormously generous gift supports the ...
... Washington DC (September23, 2009) SAGE is partnering with the ... in 2010. A peer-reviewed quarterly journal, Cartilage will ... many types of researchers and clinicians involved in cartilage biology ... Cartilage is edited by Roy D. Altman, M.D., ...
... H1N1 influenza could slow growth in key industries and ... of 2009, says a health economist in the University of ... travel are vitally important sectors in the economy of many ... severity of the spread of the virus, consumers and businesses ...
Cached Medicine News:Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 2Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 3Health News:R. Kerry Clark and Robert J. Palmisano Join Bausch & Lomb Board of Directors 2Health News:Society of Interventional Radiology Foundation receives $1 million legacy gift 2Health News:Swine flu could wreak more havoc on US economy, says UAB economist 2